ScreenerHero

CLDICalidi Biotherapeutics Inc. Common Stock

AMEX · US · Healthcare · Biotechnology · calidibio.com
1.340USD-2.90%Mkt Cap: 3.46M $P/E: —

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatm…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.46M $
Enterprise Value1.35M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.91M $
Revenue/Share—
Last Price1.340 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.49
PEG—
EV/EBITDA-0.08
EV/Revenue—
P/S—
P/B0.61
EPS (TTM)-37.04
EPS (Forward)-0.90
52W Range
1.2900% of range86.18
52W High86.18 USD
52W Low1.290 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-529.56%
ROA-224.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.29M $
CapEx (TTM)120.00K $
FCF Margin—
FCF Yield-289.27%
Net Debt-2.13M $
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity0.68
Current Ratio1.68
Quick Ratio1.34
Book Value/Sh2.213 USD
Cash/Share1.570 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:16
Split DateJul 31, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.58M
Float2.56M
Insiders0.87%
Institutions1.42%
Short Interest
Short Ratio0.6d
Short % Float9.54%
Short % Out.9.46%
Shares Short231.32K
Short (prev mo.)267.25K
Technical
SMA 501.993 (-32.8%)
SMA 2009.519 (-85.9%)
Beta1.33
S&P 52W Chg19.18%
Avg Vol (30d)359.82K
Avg Vol (10d)155.64K
Technical Indicators
RSI (14)32.8
MACD-0.1900
MACD Signal-0.1876
MACD Hist.-0.0024
BB Upper1.907 USD
BB Middle1.621 USD
BB Lower1.335 USD
BB Width35.31%
ATR (14)0.1848 USD
Vol Ratio (20d)0.12x